Chemotherapy-induced amenorrhea and other clinical and pathological parameters in the prognosis of breast cancer patients.
147 stage II pre- and perimenopausal breast cancer patients were treated with cyclophosphamide-methotrexate-5-fluorouracil (CMF)- based adjuvant regimens. 103 (72%) patients became amenorrheic during or immediately after the end of the chemotherapy program. Univariate analyses for age, menstrual status, nodal involvement, grading, estrogen and progesterone receptor status indicated no correlation between induction of amenorrhea and a significant prolongation of overall and disease-free survival. Multivariate analyses confirmed that young age at diagnosis, increasing number of infiltrated nodes, negative progesterone receptor status and grade 3 tumors are associated with a worse prognosis. Our results suggest that no benefit is expected in women with drug induced amenorrhea after CMF adjuvant treatment.
Toma
S
S
Institute of Oncology, University of Genoa, Italy.
Repetto
L
L
Giacchero
A
A
Coialbu
T
T
Costantini
M
M
Addamo
G F
GF
Guido
T
T
Rosso
R
R
D000328:Adult; D000568:Amenorrhea / Q000139:chemically induced* / Q000503:physiopathology; D000704:Analysis of Variance; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000503:physiopathology; D017024:Chemotherapy, Adjuvant; D002945:Cisplatin / Q000008:administration & dosage; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D008593:Menopause / Q000502:physiology; D008727:Methotrexate / Q000008:administration & dosage; D008875:Middle Aged; D015999:Multivariate Analysis; D010053:Ovary / Q000503:physiopathology; D011379:Prognosis; D012189:Retrospective Studies
D002945:Cisplatin; D005472:Fluorouracil; D008727:Methotrexate